Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A missing step in a metabolic pathway leads to the build-up of toxic compounds, and the lack of materials essential for normal function. Therapeutic options are currently limited: diet supplements or restrictions, or organ transplantation. Professor Yue studies the shape and function of these defective enzymes, in order to eventually develop new small molecule drugs.

Q: What is a metabolic disease?

Wyatt Yue: In the human body there are many chemical reactions taking place in order to degrade the unwanted toxic materials in the cell, and also to generate the essential compounds and materials necessary for normal function. A metabolic disorder is one in which a particular chemical reaction step is defective. It is a little bit like a factory production assembling line, where a particular assembling step is missing its worker. This this leads to the build-up of the unwanted toxic material before the assembling step, and also the lack of the product materials after that assembling step. In the human body these workers are known as enzymes.

Q: What causes this kind of metabolic disease?

WY:The majority of these metabolic disorders are genetic conditions. This means that the molecular cause of the disease is a mutation in the gene responsible for the enzyme or responsible for the chemical reaction. The mutations are usually inherited in autosomal recessive manner, meaning that the patient will inherit a defective copy of the gene from the mother and a defective copy of the gene from the father.

Q: How can we treat this type of genetic metabolic disorder?

WY:There are currently very few therapeutic options available for these disorders. Current mainstay of treatment is the management of symptoms in the patient, the restriction of dietary intake of certain food ingredients, and also the supplementation of nutrients and certain detoxifying agents in the diet. In some diseases organ transplantation is possible. Clearly there is a lack of small molecule drugs available for these metabolic disorders which are an area of my interest.

Q: What are the most important lines of research which have emerged in this area in the past 5-10 years?

WY:The past decade has seen some technological advances in three aspects which have implications in the diagnosis and treatment of the metabolic disorders. The first is the use of next generation sequencing technology to specifically identify and pin point the mutation on the gene. The second is the use of mass spectrometry methods for detection in new-born screening programmes; these are nationwide programmes to identify infants that have the metabolic disorders. The third are some novel discovery in new approaches to treat disorders, for example by replacing the gene that is defective and also replacing the defective enzyme.

Q: Why does your line of research matter & why should we fund it?

WY: My research focuses on the root cause of these disorders, which are the defective enzymes. Enzymes are proteins and we believe that understanding the 3D shapes and the properties of these proteins is the essential first step in understanding the molecular reasons of the defect, and also to design new small molecule drugs for the treatment of these disorders. My line of research is important because of two reasons. The first is that there are unanswered questions. While there are hundreds of known metabolic disorders, new ones are continually identified, many of which are poorly understood at the moment. The second reason is that there is a substantial need. While metabolic disorders are rare individually, collectively they affect 1-3% of the world population; 1 in 1000 infants are known to inherit a metabolic disorder, which therefore creates a health burden in society.

Q: How does your research fit within translational medicine in the department?

WY: My research adopts a transitional approach: I collaborate substantially with clinicians and geneticists who are at the forefront of identifying the mutations and the diseases. I collaborate with the drug developers and the pharmaceutical industry to find new ways of designing small molecule drugs. I also collaborate with patient groups to disseminate our experimental data and to answer any questions they may have on the scientific aspects of the diseases. The objective is to create a platform, where our basic scientific understanding in the bench can be brought closer to the clinic and onwards to the patients.

Wyatt Yue

Metabolic and Rare Diseases

Professor Wyatt Yue explores how genetic defects lead to disease at the molecular level, by determining 3D structures and biochemical properties of enzymes and protein complexes linked to congenital genetic errors. Professor Yue works closely with clinicians and paediatricians to decipher the underlying genetic, biochemical and cellular mechanisms of these diseases. His long-term aim is to help design novel therapeutic approaches for metabolic diseases.

More podcasts related to Translational & Clinical

Anna Gloyn: Genetics and Diabetes

Predictions suggest that by 2030, 366 million people worldwide will be affected by diabetes, a disease which already uses 10% of the NHS budget. Continued breakthroughs in the area of genetics related to different types of diabetes enable better diagnosis and treatment for patients and identify novel pathways that can be targeted for therapeutic interventions.

Erika Mancini: Chromatin Remodelling

Chromatin plays an important role in the regulation of gene expression. The movement of nucleosomes, packing and unpacking DNA, is governed by chromatin remodelling ATPases. Malfunctions in the regulation of chromatin structure often leads to complex multi-system diseases and cancer, notably leukemia.

Diabetes and Genomics by Mark McCarthy

Diabetes and obesity are both major challenges for global healthcare, with the social, health and economic costs over the next fifty years being in the ‘trillions’ of dollars. Genetics is one of the more important tools for developing a systematic understanding of the disease and how best to treat it in different patients.

Silvia Paracchini: Dyslexia and Genetics

Dyslexia is an impairment in learning to read that affects up to 10% of children; it can have profound effects on an individual life. Dyslexia has an important genetic component; candidate genes control important stages during foetal brain development. Understanding the biology of dyslexia could help us design more effective diagnostic criteria and treatment plans.

Claire Palles: Gastrointestinal cancers

The gastrointestinal track is responsible for more cancers than any other system. A condition called Barrett's oesophagus, characterised by a change in the cells lining the oesophagus, can lead to oesophageal adenocarcinoma. Only few people with Barrett's oesophagus will go on to develop cancer, and genome sequencing studies aim to identify genetic risk factors and therefore better target high-risk patients.

Antonio Velayos-Baeza: Rare neurological disorders

ChAc is a rare progressive neurological disorder caused by mutations in a very complex gene. A better understanding of the biology underlying this disease helps develop better diagnostic tools, and opens up the possibility of discovering targets for possible future treatments.

Zamin Iqbal: Computation and genetics

Resistance to drugs in bacteria can be aquired by swapping genes between individual bacteria. Computer programs developed by Dr Iqbal enable doctors to predict which antibiotics will be met with drug resistance, enabling the selection of the right drug. His work also enables the tracking of an infection from patient to patient, as well as the tracking of the spread of an infection within a hospital.

Gerton Lunter: The evolution of the genome

Computational and stastistical methods help us understand evolution as well as genetic disease. Looking at our genomes opens up clinical possibilities, for example in cancer, allowing more genes to be looked at - more quickly and more cheaply, wich can impact prognosis and treatment selection.

Catherine Green: DNA replication and Cancer

The process of DNA replication is complex, and mistakes can lead to genome instability. Surveillance systems are not always successful which results in mutations that have the potential to inactivate genes or change their activity. This can lead to cancer, and many chemotherapeutic drugs are designed to disrupt DNA replication. A better understanding of these mechanisms can help us develop new drugs with reduced side effects.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.